Recent Updates
Recently added Catalysts

Darinaparson

Phase 2

Multiple Myeloma | Small Molecules | Oncology |Alaunos Therapeutics, Inc.|Trials Updated: Sep 29, 2026

Darinaparson development status

Highest phase Phase 2
Registered trials 2 across 2 sponsors since Jan 2007

Darinaparson target and mechanism

ModalitySmall Molecules

Also known as ZIO-101

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials4
Total Enrollment104

FDA Designations

No designations recorded

Darinaparson clinical trials

Darinaparson · 4 trials · 7 indications

Phase 2 1Phase 1/2 1Phase 1 2
NCT00423644A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bMultiple Myeloma
COMPLETED17 Analytics
PHASE2COMPLETED
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Multiple MyelomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Response Rate
6 months
Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03
6 months
Phase II efficacy using EMBT criteria.
6 months
Safety
6 months
toxicities
6 months

Secondary Endpoints

Survival (overall and progression free)
6 months
toxicities
6 months
Pharmacokinetics of ZIO-101
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ArmEXPERIMENTAL -

Interventions

NameTypeDescription
DarinaparsonDRUG420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
ZIO-101 (Darinaparsin)DRUGIV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria 1. Subjects with a confirmed diagnosis of active multiple myeloma with measurable protein criteria present to evaluate response. Measurable disease is defined as having at least one of the following criteria within 28 days prior to registration: 1. Serum M-protein level \> 0....

Countries:United StatesCanada
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 338 trials

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT00423644TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00423644TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00423644TRIAL_REMOVED: changed

Frequently asked questions about Darinaparson

What is Darinaparson used for?

Darinaparson is an investigational small molecule being studied for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. It has been evaluated in a Phase 2 clinical trial in patients with advanced multiple myeloma. It is not an approved therapy and remains in clinical development.

Who is developing Darinaparson?

Darinaparson is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company sponsored the Phase 2 clinical trial of the drug in advanced multiple myeloma conducted in the United States.

What phase is Darinaparson in?

Darinaparson is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The completed study was an uncontrolled, non-randomized, open-label trial that enrolled 17 patients with advanced multiple myeloma.

What clinical trials is Darinaparson in?

Darinaparson has been studied in one clinical trial, NCT00423644, titled A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b. The trial was a completed Phase 2 study conducted in the United States that enrolled 17 patients aged 18 years and older.

Is Darinaparson the same as ZIO-101?

Yes, Darinaparson is also known as ZIO-101. The Phase 2 trial in advanced multiple myeloma was conducted under the name ZIO-101, so searches for either name refer to the same investigational small molecule developed by Alaunos Therapeutics.